KOSDAQElectrical Equipment363250

Genesystem

₩3,990▼ 2.68%2026-11-18 close
Market Cap
₩33.9B
Turnover
₩29,903,630
Volume
7.5K
Shares out.
8.5M
PER
—
PBR
—
EPS
-₩634
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

From molecular diagnostics toward power equipment, under continued losses

Genesystem is shifting its center of gravity from molecular diagnostics, where revenue has shrunk sharply, to power equipment after a 2026 change of control and the purchase of a power-equipment subsidiary, but the financial effect has yet to be verified in periodic reports.

  1. 1

    Revenue for 2025 was KRW 381 million, down 68.4% year on year, and the operating loss was KRW 9.69 billion. The company posted losses for four consecutive years from 2022 through 2025.

  2. 2

    Revenue for the third quarter of 2026 was KRW 7.69 billion, and net income attributable to controlling shareholders turned to a KRW 4.18 billion profit. The subsidiary consolidation overlaps the same quarter.

  3. 3

    Genesystem acquired 100% of a power-equipment subsidiary for KRW 10.5 billion on July 30, 2026, with an absorption merger scheduled for December 18, 2026. The subsidiary's 2025 revenue was about KRW 23.97 billion.

  4. 4

    Funding in 2026 came from KRW 6 billion in rights issues and a KRW 5.8 billion convertible bond, while a KRW 32 billion balance for property acquired by the subsidiary remains outstanding.

  5. 5

    The standalone revenue threshold for designation as a KOSDAQ administrative issue rises to KRW 5 billion from the 2026 business year, and standalone revenue for the first three quarters of 2026 was KRW 284.9 million.

02

Business structure

Genesystem develops, manufactures and services point-of-care molecular diagnostic solutions, supplying diagnostic equipment together with test kits. As of the end of the third quarter of 2025, diagnostic kits accounted for about 50.53% of consolidated revenue and molecular diagnostic equipment for about 23.33%.

Products are mainly delivered to overseas customers in Europe and Asia, with a focus on developing countries that lack diagnostic infrastructure after COVID-19.

In India, the company signed a supply contract worth USD 20 million (about KRW 29.5 billion) covering tuberculosis test kits and molecular diagnostic equipment, running from December 30, 2024 to March 28, 2027, with Genetix Biotech Asia.

The company said a separate supply agreement with a local distributor in India was not carried out, leaving a planned large revenue stream unrealized. In 2026 the business mix began to change.

On July 30, 2026, the company acquired 100% of a subsidiary that makes measuring and protective devices for switchboards for KRW 10.5 billion. That subsidiary's 2025 revenue was about KRW 23.97 billion and its net income was about KRW 383.57 million.

Management has said power equipment will become the main business, while molecular diagnostics will remain a small share of revenue for now.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩90,050,279-₩2.3B−2518.5%
2025Q4₩200M-₩3B−1900.8%
2026Q1₩300M-₩1.6B−490.0%
2026Q2₩400M-₩1B−221.7%
2026Q3₩7.7B-₩800M−9.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩3.7B-₩6.6B-₩9B−180.8%−25.6%17.3%
2023₩900M-₩9.5B-₩7.9B−1057.3%−28.8%26.9%
2024₩1.2B-₩10.1B-₩8.9B−837.6%−46.3%36.7%
2025₩400M-₩9.7B-₩12B−2541.0%−152.3%85.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue moved from KRW 3.65 billion in 2022 to KRW 897 million in 2023 (down 75.4% year on year), KRW 1.21 billion in 2024 (up 34.6%), and KRW 381 million in 2025 (down 68.4%). 2022 was the largest year in the period and 2025 the smallest.

The operating loss was KRW 6.6 billion in 2022, KRW 9.48 billion in 2023, KRW 10.1 billion in 2024 and KRW 9.69 billion in 2025, a run of four consecutive loss-making years from 2022 through 2025. Revenue rose in 2024, yet the operating loss widened, so the recovery in sales did not translate into better profit.

The operating margin was -180.8% in 2022, -1,057.3% in 2023, -837.6% in 2024 and -2,541.0% in 2025. Because the revenue base shrank, the ratio deteriorated sharply, meaning fixed costs far exceeded sales.

The company attributed the 2025 revenue decline to weaker demand for molecular diagnostics after the COVID-19 endemic phase, a failed supply agreement in India and delayed next-generation equipment launches.

Net loss attributable to controlling shareholders was KRW 9 billion in 2022, KRW 7.92 billion in 2023, KRW 8.92 billion in 2024 and KRW 12 billion in 2025. Net loss including non-controlling interests was KRW 14.7 billion in 2025, larger than the controlling-shareholder figure.

Operating cash flow was negative every year from 2022 to 2025, at KRW -6.88 billion in 2025.

Quarterly revenue went from KRW 90.05 million in the third quarter of 2025 to KRW 158 million in the fourth quarter, KRW 329 million in the first quarter of 2026, KRW 432 million in the second quarter, and KRW 7.69 billion in the third quarter, up 1,678.9% from the prior quarter.

The operating loss narrowed from KRW 3.01 billion in the fourth quarter of 2025 to KRW 1.61 billion, KRW 958 million and KRW 761 million in the first three quarters of 2026.

Because the third-quarter revenue jump falls in the same quarter as the subsidiary's acquisition on July 30, 2026, consolidation effects and existing-business effects need to be separated by segment.

Net income attributable to controlling shareholders of KRW 4.18 billion in the third quarter is a turn to profit that exceeds the operating loss, so the non-operating income composition is a point to examine in the 2026 annual report.

Over the last four quarters, the cumulative net loss attributable to controlling shareholders was KRW 4.07 billion.

05

Industry analysis

The core molecular diagnostics market has weakened since pandemic-era demand faded. Standalone revenue fell from KRW 13.2 billion in 2021 to KRW 3.7 billion in 2022 and about KRW 380 million in 2025. Domestic molecular diagnostics peers have also faced a post-endemic slump, so the weakness is not unique to the company.

India remains a market where diagnostic infrastructure is thin, and the company holds product approvals there for tuberculosis and hepatitis B and C test kits. In power equipment, listed peers include LS ELECTRIC, Hyosung Heavy Industries, HD Hyundai Electric, Cheryong Electric, Sanil Electric and Iljin Electric.

Genesystem enters this field with far smaller capital and revenue scale than these companies. The subsidiary being acquired makes measuring and protective devices, and its 2025 revenue of about KRW 23.97 billion is well above Genesystem's own revenue, so the weight of the business has moved toward the subsidiary.

How much this transition benefits from power-equipment demand cannot be quantified from disclosures alone, and the subsidiary's order backlog and revenue trend should be checked in future periodic reports.

06

Outlook

The outlook rests on dated corporate actions. A extraordinary shareholder meeting on December 18, 2026 will vote on a name change, relocation of the head office from Daejeon to Incheon, and additional business purposes.

The absorption merger of the power-equipment subsidiary takes effect on the same date, with merger registration expected on December 21, 2026. The subsidiary resolved to buy land and buildings in Seo-un-dong, Incheon, for KRW 32 billion, with the balance payment moved up to November 30, 2026.

The company also decided to sell its Daejeon headquarters land and buildings for KRW 7.3 billion.

On November 16, 2026 it decided to take over a hair-care wholesale business for KRW 3.3 billion, with the transfer scheduled for November 24, 2026; 81.6% of the transferred assets are inventory, and three related trademarks are still pending registration.

The company has said its prior health-supplement distribution produced positive results in revenue and profit, which underlies its plan to expand consumer businesses. The supply contract in India runs to March 28, 2027.

The most immediate test on the administrative-issue threshold is the gap between the KRW 5 billion standalone revenue requirement for the 2026 business year and standalone revenue of KRW 284.9 million for the first three quarters of 2026.

07

Valuation

PER
—
PBR
—
ROE
-27.6%
EPS
-₩634
BPS
—
Dividend per share
₩0

Because the last four quarters were loss-making, a price-to-earnings ratio is not calculated, and the company pays no dividend. On a price-to-book basis, market capitalization sits well above the controlling-shareholder equity, so the premium over net asset value is large.

The premium can be read as reflecting how the market values the earnings structure after the shift to power equipment and the consolidation of the subsidiary, rather than the molecular diagnostics business.

Total equity was KRW 7.75 billion at the end of 2025, with controlling-shareholder equity of KRW 7.85 billion, both reduced by accumulated losses. The debt-to-equity ratio rose from 17.3% in 2022 to 85.8% in 2025, showing debt growing quickly relative to equity.

Funding in 2026 came from rights issues and a convertible bond, but much of it is going to subsidiary investment and property payments. Trading in the stock was halted for one day on November 16, 2026 due to a business transfer disclosure.

Profit trends are visible only in direction, namely the third-quarter turn to profit and the narrowing operating loss, so any valuation comparison is more accurate once the full-year income structure in the 2026 annual report is available.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Scale gap in the power-equipment business

The subsidiary's 2025 revenue of about KRW 23.97 billion is dozens of times Genesystem's own revenue of KRW 381 million. Its net income was about KRW 383.57 million. If this business, acquired on July 30, 2026, is fully consolidated, the revenue base could change materially.

Quarterly results turning in direction

Revenue increased in each quarter from the fourth quarter of 2025 through the third quarter of 2026. The operating loss narrowed from KRW 3.01 billion to KRW 761 million, and the third quarter produced a KRW 4.18 billion profit attributable to controlling shareholders.

Existing India contract and approvals

The USD 20 million supply contract with Genetix Biotech Asia remains in force until March 28, 2027. The company has product approvals from India's regulator for tuberculosis and hepatitis B and C test kits. If public tenders in India resume, they could provide a path to revenue recovery.

09

Bear factors

Four straight loss years on a small revenue base

Revenue was KRW 381 million and the operating loss KRW 9.69 billion in 2025. The operating margin of -2,541.0% is far worse than -180.8% in 2022. The company has posted losses for four consecutive years from 2022 through 2025, and operating cash flow was negative every year.

Dependence on external funding and thin cash

Rights issues in February and March 2026 raised KRW 6 billion. The KRW 5.8 billion convertible bond issued in 2026 carries a 0% coupon, a 6% yield at maturity and matures on October 8, 2029. Standalone cash and cash equivalents at the end of the third quarter of 2026 were only about KRW 117.5 million.

Gaps in execution of the legacy business

A USD 20 million agreement with an Indian local distributor was not carried out, and next-generation equipment launches were delayed. The company has said molecular diagnostics will not account for a large share of revenue for now. With the recovery case for the legacy business weaker, executing the transition is the central challenge.

10

Risk factors

Financial and liquidity

At the end of 2025, total liabilities were KRW 6.65 billion and total equity KRW 7.75 billion, with a debt-to-equity ratio of 85.8%. Operating cash flow was negative every year. Adding the KRW 32 billion property balance and borrowing needs could lead to further funding.

The company has said the subsidiary will borrow from outside financial institutions and that the financial burden will not be large.

Listing requirements and administrative designation

The standalone revenue threshold for technology-listed companies rises to KRW 5 billion from the 2026 business year. Standalone revenue for the first three quarters of 2026 was KRW 284.9 million.

Press reports say reaching the threshold by year-end is tight, and the company is pursuing short-term revenue through a business transfer alongside its diversification.

Governance and related-party dealings

On March 31, 2026, the largest shareholder changed from the founder, holding 12.85%, to a investment partnership holding 16.81%. According to press reports, the seller of the Incheon property that the subsidiary is buying for KRW 32 billion is a wholly owned unit of a fund held by the new largest shareholder's side. A company official said an external appraisal was used.

11

What to watch next

  1. November 24, 2026

    Scheduled date for the business transfer of a hair-care wholesale unit. The scale of inventory and revenue contribution after transfer is the key point.

  2. November 30, 2026

    Balance payment date for the subsidiary's Incheon property. It will show how the purchase is funded and the scale of borrowing.

  3. December 18 and December 21, 2026

    Extraordinary shareholder meeting to vote on the name change, head-office relocation and added business purposes, with the absorption merger of the subsidiary taking effect the same day. Merger registration is scheduled for December 21.

  4. December 31, 2026

    End of the 2026 business year, which sets the standalone revenue test of KRW 5 billion for administrative-issue designation.

  5. March 28, 2027

    End of the supply contract term with Genetix Biotech Asia in India. Execution levels and any extension will indicate the direction of Indian revenue.

12

Overall view

Genesystem is in a transition period in which molecular diagnostics revenue fell to KRW 381 million in 2025 and losses have continued for four consecutive years.

In 2026 the company has carried out a change of largest shareholder, rights issues and a convertible bond, the acquisition and absorption merger of a power-equipment subsidiary, and a property transaction.

The third quarter of 2026 showed revenue of KRW 7.69 billion and a turn to net income attributable to controlling shareholders of KRW 4.18 billion, but the subsidiary consolidation falls in the same quarter, so segment reporting is needed to separate business improvement from consolidation effects.

Bullish points are the subsidiary's revenue scale, a narrowing quarterly operating loss, and the remaining term of the Indian contract.

Bearish points are dependence on external funding, the risk of falling short of the administrative-issue revenue threshold, and borrowing and related-party structures tied to the acquisition. The debt-to-equity ratio rose from 17.3% in 2022 to 85.8% in 2025.

Management has said power equipment will become the main business, but those results are not yet verifiable in periodic reports. The next checkpoints are the annual operating income composition and segment revenue in the 2026 annual report, and the execution level when the Indian contract term ends on March 28, 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.fnguide.com
  2. samsungpop.com
  3. news.nate.com
  4. newstomato.com
  5. digitaltoday.co.kr
  6. digitaltoday.co.kr
  7. pharm.edaily.co.kr
  8. kormedi.com
  9. ibtomato.com
  10. stockvery.com
  11. m.news.nate.com
  12. topstarnews.net
  13. topstarnews.net
  14. dealsite.co.kr
  15. news.nate.com
  16. specialtimes.co.kr
  17. mna.bridgecode.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis